Last reviewed · How we verify

AMPHASTAR PHARMS INC — Portfolio Competitive Intelligence Brief

AMPHASTAR PHARMS INC pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cortrosyn tetracosactide marketed Adrenocorticotropic Hormone [EPC] Melanocortin receptor 4 Oncology 1970-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Bracco · 1 shared drug class
  3. Fresenius Kabi · 1 shared drug class
  4. Guna spa · 1 shared drug class
  5. Mallinckrodt Ireland · 1 shared drug class
  6. QUESTCOR PHARMA · 1 shared drug class
  7. Rad Neurim Pharmaceuticals Eec Sarl · 1 shared drug class
  8. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AMPHASTAR PHARMS INC:

Cite this brief

Drug Landscape (2026). AMPHASTAR PHARMS INC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amphastar-pharms-inc. Accessed 2026-05-21.

Related